This message was sent to ##Email##
|
|
|
|
|
AST
Now through November 30, 2018, the AST is accepting nominations for its 2019 Board of Directors. If you are interested in joining the AST board, or know someone who is, we encourage you to submit your nomination.
READ MORE
AST
We just launched the 2018 COP giving contest: The Donation Derby. Watch this race, as the COPs compete for two prizes and fundraise for their upcoming initiatives. All donations made by COP members until the end of the year will count towards this contest, so be sure to check it out today.
READ MORE
AST
Join us for an interactive discussion on personalized medicine at the 2019 Cutting Edge of Transplantation (CEoT) meeting in Phoenix, AZ. Early bird registration is now open.
READ MORE
 |
|
The Thompson Liver / Oncology System provides surgeons with the ability to obtain stable, versatile retraction for liver transplants, liver resections, oncology, and obesity cases. Multi-planed retraction and unlimited flexibility for the most complex abdominal and pelvic cases. Call 1-800-227-7543 to start your free trial.
|
|
AST
As an AST member, access to free or discounted educational resources are included in your membership. These diverse educational resources offer materials relevant to the transplant professional in every stage of their career – from basic trainee lessons to webinars on specialized topics. LEARN MORE
|
|
AST
Comprehensive Trainee Curriculum (CTC) is a great way to expand your transplant knowledge. This feature is an online educational platform that features dozens of webinars on various concentrations of transplantation.
READ MORE
| Upcoming Education Events
|
    |
AST
Transplant Metrics - Should We Enforce or Rewrite the Final Rule?
November 14, 2018 | 2 pm ET | Online Activity
For more information, click here.
Inhibiting inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance
November 15, 2018 | 4 pm ET | Online Activity
For more information, click here.
Psychosocial Aspects of Transition of the Newly Adult, New Patient
November 28, 2018 | 2 pm ET | Online Activity
For more information, click here.
|
The study is designed to explore an investigational drug-maribavir-in stem cell transplant and solid organ transplant recipients whose CMV infections are not responding to current treatments. This investigational drug is given as an oral pill. Please visit to learn more about the SOLSTICE study.
|
|
|
|
|
The first and only clinically and analytically validated blood test that measures donor-derived cell-free DNA (dd-cfDNA), a direct indicator of kidney injury
Covered by Medicare
AlloSure 101 – Development & Summary Webinar – view
|
|
|
|
|
AST
Family Planning in SOT
After participating in this webinar, the learner will be able to:
- Discuss the effect of end organ disease and subsequent transplant on fertility in women.
- Review the safety and efficacy of hormonal contraceptive options in transplant recipients.
- Discuss pre-conception recommendations for transplant recipients, including timing and immunosuppression management.
- Review maternal and fetal outcome data in both transplant recipients and living organ donors.
- Provide resources for additional patient and provider education on reproductive health after transplantation.
READ MORE
AST
An education committee subcommittee focusing on community education has recently been developed. They ask that you please share the following survey link with your patients, donors, and caregivers to help guide their efforts.
READ MORE
|
The articles included in this email are for informational use only and are not endorsed by the AST.
|
The American Journal of Transplantation
Deceased donor kidney transplantation (DDKT) rates for highly sensitized (HS) candidates increased early after implementation of the Kidney Allocation System (KAS) in 2014. However, this may represent a bolus effect, and a granular investigation of the current state of DDKT for HS candidates remains lacking.
READ MORE
Transplantation
Kidney transplantation confers substantial survival and quality of life benefits for many patients with end-stage kidney disease compared with dialysis, but complications and side-effects of immunosuppression can impair participation in daily life activities. Life participation is a critically important patient-reported outcome for kidney transplant recipients but is infrequently and inconsistently measured in trials. We convened a consensus workshop on establishing an outcome measure for life participation for use in all trials in kidney transplantation
READ MORE
Transplantation
The opioid abuse epidemic and the deaths of otherwise healthy individuals due to drug overdose in the United States has major implications for transplantation. The current extent and safety of utilization of liver and kidney grafts from donation after cardiac death (DCD) donors who died in the context of opioid overdose is unknown.
READ MORE
Liver Transplantation
Ex‐situ normothermic machine perfusion (NMP) might minimize ischemia/reperfusion injury (IRI) of liver grafts. Twenty primary liver transplants recipients of older grafts (≥70 years) were randomized 1:1 to NMP or cold storage (CS). The primary study endpoint was to evaluate graft and patient survival at 6 months posttransplantation. The secondary endpoint was to evaluate: IRI by means of peak transaminases within 7 days after surgery; incidence of biliary complications at month 6, and evaluation of liver and bile duct biopsies.
READ MORE
Liver Transplantation
Nonalcoholic Steatohepatitis (NASH) is one of the top three indications for liver transplantation in western countries. It is unknown whether renal dysfunction at the time of liver transplantation has any effect on post‐liver transplantation outcomes in recipients with NASH.
READ MORE
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
